Aiming to offer an exclusive digital network for medical staff, Novartis Vietnam Ltd. has recently teamed up with Docquity Holdings Pte., Ltd. to bring the Docquity online platform to Vietnam.
Docquity is the largest professional network in the healthcare section in Asia, aiming to create a digital environment for medical staff to share their own specialised knowledge and experience. In Vietnam, Novartis – a leading pharmaceutical and healthcare company based in Switzerland – is co-operating with the firm to offer more effective and high-quality treatments to patients.
In terms of collaboration, Novartis will co-operate with medical organisations to conduct online seminars (on Zoom, MS, and other platforms) and then share these links on the Docquity platform which offers several private channels divided by expertise such as pulmonology, cardiology, and endocrinology, among others. Moreover, recordings of live webinars will also be posted on this platform so that healthcare professionals who missed the live event would be able to view them on demand.
|Docquity offers different sections aligned with specific expertise |
In addition, participating professionals can leave comments to share their opinions and questions when the seminar takes place as well.
“The collaboration of Novartis and Docquity will contribute to the digital transformation of the healthcare sector, and is a step forward to realise the goal of turning Vietnam into a digital nation,” said Amitabh Dube, country president of Novartis Vietnam. “This is also an investment in building an ecosystem for better solutions and new ideas to solve real-world healthcare challenges.”
|Novartis creates a new medical network in Vietnam |
Although only established in 2015, Docquity has brought a great deal of benefits to many countries. Notably, Docquity has played a crucial role in training and motivating medical volunteers to participate in preventing the healthcare system from becoming overloaded amid the ever-increasing number of COVID-19 cases in Indonesia.
|In Vietnam, Novartis is co-operating with Docquity to offer more effective and high-quality treatments to patients. |
“Doctors are our heroes and Docquity is excited to partner with Novartis and the medical community in Vietnam and extend our vision of supporting doctors in Vietnam with quality scientific and clinical engagement programmes on the Docquity platform that has been localised for Vietnam,” said Amit Vithal, co-founder and chief business officer of Docquity.
Within this collaboration, Novartis aims to help leverage the advantage of technology and data to provide a convenient and efficient platform helping healthcare professionals access specialised information more easily. This is also a milestone for Novartis in its journey to bring new technology to the medical field in Vietnam.
In early 2020, Novartis Vietnam Ltd. became the first multinational pharmaceutical company to successfully transform into a foreign-invested enterprise and fully operationalise its import activities. Through long-term commitments Novartis is supporting the domestic healthcare system and contributing to the socioeconomic development of the country. Novartis is a leader in innovative medicines across many therapeutic areas: oncology, cardiovascular (hypertension, heart failure, diabetes), respiratory (asthma, COPD); ophthalmology; pain relief; neuroscience, dermatology and immunology, cell and gene therapy, and more. The company is also a leader in high quality generics through its Sandoz unit and one of the largest investors in clinical trials in Vietnam.